机构:[1]Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Renal Research Institution, Beijing University of Chinese Medicine, Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China[2]Zhanjiang Key Laboratory of Prevention and Management of Chronic Kidney Disease, Guangdong Medical University, Zhanjiang, Guangdong 524001, China
Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease, and satisfactory therapeutic strategies have not yet been established. The Shen-Yan-Fang-Shuai Formula (SYFSF) is a traditional Chinese formula composed of Astragali radix, Radixangelicae sinensis, Rheum officinale Baill, and four other herbs. It has been widely used as an effective treatment for DKD patients in China. However, little is known about the molecular mechanisms underlying SYFSF's renoprotection. In this study, we compared the protective effect of SYFSF to irbesartan on the histology and renal cells in type 2 DKD rat model and high-glucose (HG) cultured mesangial cells, respectively. We found that SYFSF could significantly decrease urinary albumin, cholesterol, and triglyceride. And a decrease in serum creatinine was also found in SYFSF-treated group compared with irbesartan-treated rats. In addition, SYFSF inhibited the interstitial expansion and glomerulosclerosis in diabetic rats. Notably, SYFSF markedly downregulated the expression of MCP-1, TGF-β1, collagen IV, and fibronectin in diabetic rat models and HG-induced mesangial cell models. The renoprotection was closely associated with a reduced expression of TNF-α and phosphorylated NF-κBp65. Our study suggests that SYFSF may ameliorate diabetic kidney injury. The observed renoprotection is probably attributable to an inhibition of inflammatory response and extracellular matrix (ECM) accumulation mediated by TNF-α/NF-κBp65 signaling pathway.
基金:
This study was supported by the National Natural Science
Foundation of China (nos. 81273633/H2704 and 81570656).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类|3 区医学
小类|3 区内分泌学与代谢3 区医学:研究与实验
最新[2025]版:
大类|3 区医学
小类|3 区内分泌学与代谢3 区医学:研究与实验
第一作者:
第一作者机构:[1]Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Renal Research Institution, Beijing University of Chinese Medicine, Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China
共同第一作者:
通讯作者:
通讯机构:[1]Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Renal Research Institution, Beijing University of Chinese Medicine, Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China[2]Zhanjiang Key Laboratory of Prevention and Management of Chronic Kidney Disease, Guangdong Medical University, Zhanjiang, Guangdong 524001, China
推荐引用方式(GB/T 7714):
Jie Lv,Zhen Wang,Ying Wang,et al.Renoprotective Effect of the Shen-Yan-Fang-Shuai Formula by Inhibiting TNF-α/NF-κB Signaling Pathway in Diabetic Rats.[J].Journal of diabetes research.2017,2017:4319057.doi:10.1155/2017/4319057.
APA:
Jie Lv,Zhen Wang,Ying Wang,Weiwei Sun,Jingwei Zhou...&Yaoxian Wang.(2017).Renoprotective Effect of the Shen-Yan-Fang-Shuai Formula by Inhibiting TNF-α/NF-κB Signaling Pathway in Diabetic Rats..Journal of diabetes research,2017,
MLA:
Jie Lv,et al."Renoprotective Effect of the Shen-Yan-Fang-Shuai Formula by Inhibiting TNF-α/NF-κB Signaling Pathway in Diabetic Rats.".Journal of diabetes research 2017.(2017):4319057